Want to see ADMA full AI Analyst Report?
ADMA Stock Chart & Stats
$9.72
-$0.10(-1.19%)
At close: 4:00 PM EDT
$9.72
-$0.10(-1.19%)
Day’s Range― - ―
52-Week Range$7.21 - $20.46
Previous CloseN/A
Volume2.34M
Average Volume (3M)2.26M
Market Cap
$2.10B
Enterprise Value$2.00K
Total Cash (Recent Filing)$136.02M
Total Debt (Recent Filing)$203.84M
Price to Earnings (P/E)13.0
Beta0.91
Next Earnings
Nov 11, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.72
Shares Outstanding223,984,680
10 Day Avg. Volume1,736,847
30 Day Avg. Volume2,264,304
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)9.11
Price to Sales (P/S)8.52
P/FCF Ratio156.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.00Price Target Upside74.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.79
Revenue Forecast (FY)$534.36M
Bulls Say, Bears Say
Bulls Say
ASCENIV Adoption And GrowthASCENIV is becoming the principal growth engine, with rising physician adoption, patient starts and utilization. Sustained uptake can offset legacy-product weakness and support durable revenue expansion.
Profitability And Margin ExpansionThe shift from losses to strong profitability indicates operating leverage and improved commercial scale. Elevated gross margins provide a buffer against pricing pressure, although the relatively recent turnaround warrants continued monitoring.
Strong Cash GenerationHigh cash conversion strengthens earnings quality and gives ADMA resources to fund plasma operations, manufacturing, development programs and shareholder returns. It also improves resilience as the company scales its product portfolio.
Bears Say
BIVIGAM Volume DeclineThe expected contraction in BIVIGAM creates a material revenue gap that ASCENIV must fill. If ASCENIV adoption slows, the legacy-product decline could weaken growth, manufacturing utilization and earnings durability.
Standard IG Pricing PressurePersistent supply growth and competitive discounting can compress net pricing and margins across standard IG products. This may limit recovery in pressured volumes and reduce the earnings benefit of otherwise strong demand.
Elevated Working Capital IntensityLarge inventory and receivables balances tie up capital and increase execution, obsolescence and collection risks. Higher working-capital needs could constrain free cash flow if growth slows or distributor payments lengthen.
ADMA Biologics News
ADMA FAQ
What was ADMA Biologics’s price range in the past 12 months?
ADMA Biologics lowest stock price was $7.21 and its highest was $20.46 in the past 12 months.
What is ADMA Biologics’s market cap?
ADMA Biologics’s market cap is $2.10B.
When is ADMA Biologics’s upcoming earnings report date?
ADMA Biologics’s upcoming earnings report date is Nov 11, 2026 which is in 70 days.
How were ADMA Biologics’s earnings last quarter?
ADMA Biologics released its earnings results on Aug 05, 2026. The company reported $0.165 earnings per share for the quarter, beating the consensus estimate of $0.163 by $0.002.
Is ADMA Biologics overvalued?
According to Wall Street analysts ADMA Biologics’s price is currently Undervalued.
Does ADMA Biologics pay dividends?
ADMA Biologics does not currently pay dividends.
What is ADMA Biologics’s EPS estimate?
ADMA Biologics’s EPS estimate is 0.2.
How many shares outstanding does ADMA Biologics have?
ADMA Biologics has 223,984,680 shares outstanding.
What happened to ADMA Biologics’s price movement after its last earnings report?
ADMA Biologics reported an EPS of $0.165 in its last earnings report, beating expectations of $0.163. Following the earnings report the stock price went up 8.639%.
Which hedge fund is a major shareholder of ADMA Biologics?
Currently, no hedge funds are holding shares in ADMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADMA Biologics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (74.90% Upside)
$17.00 (74.90% Upside)
Blogger Sentiment
Bullish
ADMA Sentiment 63%
Sector Average ―
Sector Average ―
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ADMA Biologics
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
ADMA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial story driven by strong ASCENIV revenue growth (+24% YoY), meaningful margin expansion (gross margin up to 69% from 55%), improved adjusted EBITDA (+22% YoY), solid cash generation and a healthy balance sheet with active share repurchases. Offsetting risks discussed include a significant decline in legacy BIVIGAM volumes (management expects ~40%–50% decline vs 2025), ongoing competitive pricing pressure in the standard IG market, elevated working capital (inventory and receivables) and a higher effective tax rate. Management reiterated full-year guidance and highlighted clinical evidence and pipeline progress (SG-001), supporting confidence in the company’s growth trajectory despite near-term market headwinds.View all ADMA earnings summariesADMA Stock 12 Month Forecast
Average Price Target
$17.00
▲(74.90% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Protagonist Therapeutics
―
Immunovant
―
MoonLake Immunotherapeutics
―
―
Ownership Overview
3.54% Insiders
26.79% Mutual Funds
23.30% Other Institutional Investors
12.06% Public Companies and
Individual Investors